Synairgen Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Synairgen's earnings have been declining at an average annual rate of -4.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 105.5% per year.
Anahtar bilgiler
-4.1%
Kazanç büyüme oranı
2.0%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 11.5% |
Gelir büyüme oranı | -105.5% |
Özkaynak getirisi | -72.4% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Dec 09Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation
Aug 24Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?
Apr 29Companies Like Synairgen (LON:SNG) Could Be Quite Risky
Dec 27We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate
Sep 13Companies Like Synairgen (LON:SNG) Could Be Quite Risky
May 31Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Feb 06We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Oct 21We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Mar 29How Much Of Synairgen plc (LON:SNG) Do Institutions Own?
Dec 14Gelir ve Gider Dağılımı
Synairgen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -7 | 3 | 6 |
31 Mar 24 | 0 | -8 | 3 | 6 |
31 Dec 23 | 0 | -8 | 4 | 7 |
30 Sep 23 | 0 | -9 | 4 | 7 |
30 Jun 23 | 0 | -10 | 5 | 7 |
31 Mar 23 | 0 | -14 | 5 | 11 |
31 Dec 22 | 0 | -18 | 5 | 15 |
30 Sep 22 | 0 | -23 | 6 | 21 |
30 Jun 22 | 0 | -28 | 6 | 27 |
31 Mar 22 | 0 | -38 | 5 | 40 |
31 Dec 21 | 0 | -49 | 5 | 53 |
30 Sep 21 | 0 | -46 | 4 | 50 |
30 Jun 21 | 0 | -43 | 4 | 48 |
31 Mar 21 | 0 | -28 | 3 | 32 |
31 Dec 20 | 0 | -14 | 2 | 15 |
30 Sep 20 | 0 | -10 | 2 | 11 |
30 Jun 20 | 0 | -6 | 1 | 6 |
31 Mar 20 | 0 | -5 | 1 | 5 |
31 Dec 19 | 0 | -4 | 1 | 3 |
30 Sep 19 | 0 | -4 | 1 | 3 |
30 Jun 19 | 0 | -4 | 1 | 4 |
31 Mar 19 | 0 | -3 | 1 | 3 |
31 Dec 18 | 0 | -3 | 1 | 3 |
30 Sep 18 | 3 | -1 | 1 | 3 |
30 Jun 18 | 5 | 2 | 1 | 2 |
31 Mar 18 | 5 | 2 | 1 | 2 |
31 Dec 17 | 5 | 2 | 1 | 2 |
30 Sep 17 | 3 | 0 | 1 | 2 |
30 Jun 17 | 0 | -3 | 1 | 2 |
31 Mar 17 | 0 | -3 | 1 | 2 |
31 Dec 16 | 0 | -3 | 1 | 2 |
30 Sep 16 | 0 | -3 | 1 | 2 |
30 Jun 16 | 0 | -3 | 1 | 2 |
31 Mar 16 | 0 | -2 | 1 | 2 |
31 Dec 15 | 0 | -2 | 1 | 1 |
30 Sep 15 | 0 | -2 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 1 |
31 Mar 15 | 2 | 0 | 1 | 1 |
31 Dec 14 | 4 | 1 | 2 | 2 |
30 Sep 14 | 4 | 1 | 2 | 2 |
30 Jun 14 | 4 | 1 | 2 | 2 |
31 Mar 14 | 2 | -1 | 1 | 2 |
Kaliteli Kazançlar: SNG is currently unprofitable.
Büyüyen Kar Marjı: SNG is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: SNG is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.
Büyüme Hızlandırma: Unable to compare SNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: SNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Özkaynak Getirisi
Yüksek ROE: SNG has a negative Return on Equity (-72.4%), as it is currently unprofitable.